图片:Adobe
2022年6月17日

Medicines used to prevent bone loss may help lower the risk of ovarian cancer according to research by 大学的 威利斯欢乐娱人成APP.

威利斯欢乐娱人成APP researchers compared 地中海ications taken by more than 50,000名年龄超过50岁的妇女, using de-identified 地中海ical records from 2004–2013, to analyse differences in those with ovarian cancer and without.

威利斯欢乐娱人成APP School of Public Health 博士生 凯伦Tuesley said women who used nitrogen-based bisphosphonates were found to be less likely to develop ovarian cancer.

“The findings varied between ovarian cancer subtypes and included a 50 per cent lower risk for endometrioid cancers and 16 per cent for serous ovarian cancers,图斯利女士说.

“We don’t yet know why these 地中海icines may lower the risk of ovarian cancer in women, but previous studies have shown that nitrogen-based bisphosphonates can stop the disease spreading in laboratory grown cells.

“Ovarian cancer is the eighth most common cancer in 澳大利亚n women with fewer than 50 percent of patients alive five years after diagnosis.”

In 2021, there were 1720 cases of ovarian cancer diagnosed, and 83 per cent of these occurred in women aged over 50 years, according to the 澳大利亚n Institute of Health and Welfare.

超过200,000 澳大利亚ns are prescribed bisphosphonates containing nitrogen each year, making them one of the most prescribed 地中海icines of their type in the country.

The 地中海icines prevent bone loss and help reduce fractures in osteoporosis patients.

博士生导师 Associate Professor Susan Jordan said this study is important because most known risk factors for ovarian cancer cannot be easily modified.  

“Earlier studies have found 地中海icines used to treat other diseases may be useful in preventing cancer, prompting this investigation into bisphosphonates,Jordan博士说.

“Further research is needed to understand why these 地中海icines might affect ovarian cancer subtypes differently.

“We know ovarian cancer subtypes look different under the microscope and have unique risk factors.

“然而, it is important to look at each subtype separately to improve our knowledge and understanding of these cancers.

“This study may help inform 地中海icine choice for women with osteoporosis and suggest areas for further research to better understand how ovarian cancer develops.”

The paper is published in the JNCI: Journal of the National Cancer Institute.

媒体:凯伦Tuesley, k.tuesley@ciaozone.com; Associate Professor Susan Jordan, s.jordan@ciaozone.com, +61 7 336 55473; 威利斯欢乐娱人成APP Communications, 地中海.地中海ia@ciaozone.com, +61 0436 368 746.